Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002).

AAPS PharmSci Pub Date : 2004-02-09 DOI:10.1208/ps060106
Malcolm Rowland, Luc Balant, Carl Peck
{"title":"Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002).","authors":"Malcolm Rowland,&nbsp;Luc Balant,&nbsp;Carl Peck","doi":"10.1208/ps060106","DOIUrl":null,"url":null,"abstract":"<p><p>A 2-day workshop on \"Physiologically Based Pharmacokinetics (PBPK) in Drug Development and Regulatory Science\" came to a successful conclusion on May 30, 2002, in Washington, DC. More than 120 international participants from the environmental and predominantly pharmaceutical industries, Food and Drug Administration (FDA), and universities attended this workshop, organized by the Center for Drug Development Science, Georgetown University, Washington, DC. The first of its kind specifically devoted to the subject, this intensive workshop, comprising 7 plenary presentations and 10 breakout sessions addressed 2 major objectives: (1) to \"define demonstrated and potential contributions of PBPK in drug development and regulatory science,\" and (2) to \"assess current PBPK methodologies with the identification of their limitations and outstanding issues.\" This report summarizes the presentations and recommendations that emerged from the workshop, while providing key references, software, and PBPK data sources in the appendices. The first day was initially devoted to presentations setting the stage and providing demonstrated applications to date. This was followed by breakout sessions that considered further opportunities and limitations, and which extended into Day 2 to deal with developments in methodologies and tools. Although the primary emphasis was on pharmacokinetics, consideration was also given to its integration specifically with mechanism-based pharmacodynamics.</p>","PeriodicalId":6918,"journal":{"name":"AAPS PharmSci","volume":"6 1","pages":"E6"},"PeriodicalIF":0.0000,"publicationDate":"2004-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1208/ps060106","citationCount":"118","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AAPS PharmSci","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1208/ps060106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 118

Abstract

A 2-day workshop on "Physiologically Based Pharmacokinetics (PBPK) in Drug Development and Regulatory Science" came to a successful conclusion on May 30, 2002, in Washington, DC. More than 120 international participants from the environmental and predominantly pharmaceutical industries, Food and Drug Administration (FDA), and universities attended this workshop, organized by the Center for Drug Development Science, Georgetown University, Washington, DC. The first of its kind specifically devoted to the subject, this intensive workshop, comprising 7 plenary presentations and 10 breakout sessions addressed 2 major objectives: (1) to "define demonstrated and potential contributions of PBPK in drug development and regulatory science," and (2) to "assess current PBPK methodologies with the identification of their limitations and outstanding issues." This report summarizes the presentations and recommendations that emerged from the workshop, while providing key references, software, and PBPK data sources in the appendices. The first day was initially devoted to presentations setting the stage and providing demonstrated applications to date. This was followed by breakout sessions that considered further opportunities and limitations, and which extended into Day 2 to deal with developments in methodologies and tools. Although the primary emphasis was on pharmacokinetics, consideration was also given to its integration specifically with mechanism-based pharmacodynamics.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
药物开发和监管科学中基于生理学的药代动力学:研讨会报告(乔治城大学,华盛顿特区,2002年5月29-30日)。
2002年5月30日,为期两天的“药物开发和监管科学中基于生理的药代动力学(PBPK)”研讨会在华盛顿特区圆满结束。来自环境和主要制药行业、食品和药物管理局(FDA)和大学的120多名国际参与者参加了由华盛顿特区乔治城大学药物开发科学中心组织的这次研讨会。这是第一次专门针对这一主题的密集研讨会,包括7次全体会议和10次分组会议,讨论了两个主要目标:(1)“定义PBPK在药物开发和监管科学中的已证明和潜在贡献”;(2)“评估当前PBPK方法,确定其局限性和突出问题”。本报告总结了研讨会中出现的演讲和建议,同时在附录中提供了关键参考文献、软件和PBPK数据源。第一天的主要任务是做演示,搭建舞台,提供迄今为止的演示应用。接下来是讨论进一步机会和限制的分组会议,并延伸到第二天处理方法和工具的发展。虽然主要的重点是药代动力学,但也考虑到其与基于机制的药效学的具体整合。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The composite solubility versus pH profile and its role in intestinal absorption prediction cDNA Microarray analysis of vascular gene expression after nitric oxide donor infusion in rats: Implications for nitrate tolerance mechanisms Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of HIV-1 replication? Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler Allometric scaling of xenobiotic clearance: Uncertainty versus universality
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1